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Introduction 
Bronchial asthma and rhinosinusitis are inflammatory con- 
ditions which affect the lower and upper airways, respect- 
ively, and frequently co-exist. Indeed, evidence shows that 
80% of asthmatics also have rhinosinusitis, and 50% of 
patients with rhinosinusitis have asthma (1). Moreover, in 
45% of cases, the development of rhinosinusitis occurs 
before that of asthma and adequate control of rhinosinus- 
itis can improve asthma control in patients with concomi- 
tant disease (2). Both conditions are underpinned by similar 
pathological changes characterized by an intense inflamma- 
tory infiltrate of activated mononuclear cells and granulo- 
cytes of which the eosinophil is prominent (3-8). In 
addition, it is now firmly established that both conditions 
are mediated in part by the cysteinyl-leukotrienes. In both 
of these conditions, site-specific leukotrienes can be 
detected in increased quantities as compared to normal 
control subjects; their levels change in response to specific 
challenge procedures and disease exacerbations; exogenous 
administration can mimic components of the disease pro- 
cesses; and specific antagonists have been demonstrated to 
reverse components of these diseases in vitro, in vivo and in 
the real clinical setting. As compared to glucocorticoids 
(GCS), which are currently the most effective treatment 
available for asthma and rhinosinusitis, leukotriene antag- 
onists are specific in their mechanism of action and are 
thereby relatively free from serious side-effects (9,lO). At 
present, two such agents have been approved for the 
treatment of asthma by the Food and Drug Administration 
(FDA) in the U.S.A. Zileuton (Zyflo@), an inhibitor of 
5-lipoxygenase, and zafirlukast (Accolate@), an inhibitor of 
the action of LTD, at its receptor, are now available 
by prescription in the U.S.A., Ireland, and Norway. 
Pranlukast and montelukast (Singulaira) (ll), both of 
which are also inhibitors of LTD,, will likely receive 
approval before the end of 1998. Montelukast has been 
licensed in the U.K. since February 1998 as add-on therapy 
in mild to moderate persistent asthma that is inadequately 
controlled by inhaled glucocorticoids and &-agonists, and 
also for the prophylaxis of exercise-induced broncho- 
constriction. Accolate is expected to be available later in 
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1998. All agents are administered orally. This review will 
outline the background to the development of these drugs 
from the ‘molecule to the bedside’ and suggest their poten- 
tial role in the management of asthma and rhinosinusitis. 
Biosynthesis 
Leukotrienes (LTs) were discovered during the elucidation 
of a mixture of compounds referred to as the slow reacting 
substance of anaphylaxis or SRS-A. In 1940, Kellaway and 
Trethewie found that a product of an in vitro anaphylactic 
reaction in guinea-pig lung caused smooth muscle tissue 
to constrict more slowly than did histamine (12). The 
discovery of antihistamines in the 1950s allowed the 
discovery of a non-histamine component which was subse- 
quently identified as SRS-A. In view of the lack of efficacy 
of antihistamines in the management of patients with 
asthma, it seemed likely that SRS-A was involved in the 
reversible airway problems of humans with this disease. In 
1980, the composition of SRS-A was finally elucidated by 
Morris et al., Lewis, Austen and Samuelsson et al., as 
comprising leukotriene C4 (LTC,) and its biologically 
active metabolites, LTD, and LTE, (13-l 5). In addition to 
asthma and rhinosinusitus, LTs have been implicated 
in the pathogenesis of psoriasis, ischaemic heart disease, 
rheumatoid arthritis, inflammatory bowel disease, and 
malignancy. 
LTs are generated de lzovo upon cellular activation when 
arachidonic acid (AA), a 20-carbon polyunsaturated fatty 
acid, is released from nuclear membrane phospholipids by 
the action of the cytosolic enzyme phospholipase A, 
(PLA,), and is converted to the unstable intermediate LTA, 
by the enzyme 5-lipoxygenase (5-LO) in the first dedicated 
steps of leukotriene generation (16) (Fig. 1). Cytosolic 
PLA, is upregulated by inflammatory cytokines and inhib- 
ited by glucocorticoids. LTA, is then converted to either 
LTB, or LTC, depending upon the cellular availability of 
LTA, hydrolase or LTC, synthase, respectively. Multiple 
lipoxygenases exist that catalyse molecular oxygen insertion 
into arachidonic acid at either the 5-, 12-, or 15-carbon 
position. In the resting cell, 5-LO is closely bound to 
nuclear euchromatin. Upon cellular activation, 5-LO trans- 
locates to the nuclear membrane in a Ca”- and ATP- 
dependent mechanism where it binds to the 5-LO activating 
protein (FLAP). FLAP is an essential co-factor for eventual 
LT generation (17). U937 cells express FLAP but not 5-LO 
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FIG. 1. Schematic representation of leukotriene synthetic 
pathways and the enzymes catalysing specific reactions. 
FLAP, 5-lipoxygenase activating protein; HETE, 
hydroxy-eicosatetraenoic acid; HPETE, hydroperoxy- 
eicosatetraenoic acid; LT, leukotriene. 
and therefore cannot synthesize LTs. The ability to synthe- 
size LTs can be restored by transfection with a retroviral 
vector encoding the 5-LO mRNA (18). As the cellular 
synthesis of leukotrienes is limited by the requirement to 
express both 5-LO and FLAP, cells of myeloid lineage 
provide the major source of leukotriene production. Cells 
can be divided by their ability to preferentially synthesize 
LTB, or the cysteinyl leukotrienes, LTC,, LTD, and LTD,, 
depending on the intracellular predominance of either 
LTA, hydrolase or LTD, synthase, respectively. Phagocytic 
cells (monocytes, tissue, macrophages, and neutrophils) 
preferentially generate LTB,, whereas eosinophils, mast 
cells, and basophils preferentially generate cysteinyl leuko- 
triene products (19,20) (Table 1). Unlike 5-LO, LTC, 
synthase and LTAb hydrolase are widely distributed in 
mammalian cells. Thus LTA, released by a cell capable of 
generating 5-LO products may be utilized for further 
metabolism by other cells without the enzyme 5-LO. Such 
transcellular metabolism can lead to the generation of 
LTC, by cells such as endothelium, which would not 
normally generate it (21). After formation, LTB, is 
exported from the cell to exert its biological effects. If LTB, 
undergoes reuptake or is retained intracellularly, its 
catabolism/inactivation varies with cell type. Neutrophils 
inactivate LTB, by a series of three sequential oxidations of 
the C-20 carbon, while monocytes/macrophages and kidney 
mesangial cells inactivate LTB, via oxidation of the C-12 
carbon. The biological activity of each of the intermediates 
decreases and the final product is inactive when metabo- 
lized in this fashion. LTC, is metabolized to the other 
biologically active cysteinyl leukotrienes after transport 
from the cell. This occurs by enzymes that sequentially 
cleave amino acid residues to form leukotriene D4 (LTD,), 
which is then converted to the final bioactive cysteinyl 
leukotriene, leukotriene E, (LTE,). LTE, is then excreted 
directly or after N-acetylation. The cysteinyl leuko- 
trienes may also be inactivated in the local extracellular 
environment via oxidation. 
Biological Activity 
For a molecule to be implicated in any disease process such 
as asthma or rhinosinusitis, it must satisfy certain criteria. 
The mediator should mimic a component of the disease 
both in vitro and in vivo. The mediator, or its metabolite, 
should be identified in the blood, urine, or other relevant 
biological fluid, and be shown to increase temporally in 
TABLE 1. Cellular source of human leukotriene generation 
Cell 
Predominant 
leukotriene 
product 
Activating 
stimulus 
Approximate 
amount 
generated/lo6 
cells 
Neutrophils 
Eosinophils 
Peripheral blood 
Monocytes 
Alveolar macrophages 
Mast cells 
Basophils 
LTB, 
LTC, 
LTB, 
LTC, 
LTB, 
LTC, 
LTB, 
LTC, 
LTC, 
A23 187 
A23187 
A23187 
A23187 
A23 187 
A23187 
A23187 or anti-IgE 
A23187 
50 ng 
10 11g 
long 
40 ng 
70 ng 
30 ng 
30 ng 
20 ng 
long 
LTB,, leukotriene B,; LTC,, leukotriene C,; A23187, divalent calcium ionophere; AA, arachidonic 
acid (18-21). 
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TABLE 2. Biological activity of cysteinyl leukotrienes 
Activity Reference 
Augment post-capillary dermal vascular permeability 
in guinea-pigs 
Increased microvascular permeability 
Increase leukocyte adhesion to endothelial cells 
Increase mucous secretion 
Potent contractile agonists for bronchial smooth muscle 
Vasoconstriction 
Coronary vasoconstriction in sheep 
Systemic vasoconstriction in rats 
Renal vasoconstriction in rats 
Recruit granulocytes into the lamina propria of asthmatic airways (LTE,) 
(23) 
(14) 
(23) 
(26) 
(144) 
(28) 
(145) 
(146) 
(147) 
(148) 
(149) 
(150) 
association with an occurrence of the disease process in an 
animal and human model of the disease. Finally, and most 
importantly, a selective mediator antagonist should be able 
to reverse the disease component in vitro and eventually in 
the real clinical setting. LTs exert their biological effects via 
specific cell membrane receptors. The leukotriene B recep- 
tors are characterized in terms of their activation by LTB, 
as well as their antagonism by potent and selective antag- 
onists. Although the structure of these receptors has not 
been fully elucidated, two forms have been identified in 
neutrophils. These two receptor forms each have different 
affinity states: the one with high affinity transduces chemo- 
tactic and adhesion responses, and the low affinity receptor 
is responsible for granule content release and superoxide 
generation. The cysteinyl leukotriene receptors can be 
divided into two categories. Cys-LTR, responds primarily 
to LTCJLTD, and is responsive to antagonists. Cys-LTR, 
interacts with LTC, and is relatively resistant to antagonists 
(22-23). 
The main biological activities of LTB, relate to the 
augmentation of phagocytic and non-specific immune 
responses, whereas the activities of the cysteinyl-LTs 
are more directly pertinent to asthma and rhinosinusitis 
(Table 2). The latter are vastly more potent contractile 
agonists of smooth muscle than histamine, they greatly 
increase microvascular permeability, and are chemotactic 
for granulocytes, particularly eosinophils (24-27). LTC, 
and LTD, are lOOO-fold more potent than histamine in 
contracting human bronchial smooth muscle strips in vitro 
(28). 
The inhalation of leukotrienes by human subjects has 
shown potent contraction of the airways in both normal 
and asthmatic subjects and leads to airway obstruction. 
When data from different sources are combined, inhaled 
LTC, and LTD, in normal subjects are 2000 times more 
potent than histamine or methacholine in causing airway 
obstruction (29). LTE, is, however, only 40- to 60-fold 
more potent than histamine but produces a longer lasting 
bronchoconstruction in normal subjects (30). Asthmatic 
airways also respond by bronchoconstruction to inhaled 
leukotrienes but, in contrast to normal airways, exhibit 
smaller responses when compared with a reference agonist 
such as histamine or methacholine. The results of these 
studies indicate that, compared with normal airways, 
asthmatic airways are relatively less responsive to LTC, 
and LTD, but have a disproportionate hyperresponsiveness 
to the bronchoconstricting effects of LTE, (31-33). This 
indicates an important role for LTE, in bronchial asthma 
which may be due to its greater stability compared with 
other cysteinyl leukotrienes, and because it persists for the 
longest time at the site of release. 
LTs also enhance BHR in normal, asthmatic and rhinitic 
patients. Kern et al. have shown that LTD, enhanced BHR 
to methacholine by 280-590% in normal subjects (34). 
These studies were extended by Smith et al. who demon- 
strated that LTD, enhanced methacholine BHR in rhinitics 
(without asthma) and in asthmatics by three to five-fold 
and 250~850-fold., respectively when compared to normal 
control subjects (35). O’Hickey et al. have demonstrated 
that LTC,, LTD, and LTE, enhanced airway responsive- 
ness to histamine by 3.9-, 2.8 and 3.1-fold, respectively, in 
asthmatic airways (36). The effect of LTE, was partially 
abrogated by indomethacin indicating that LTE,- 
induced BHR is mediated in part by cyclooxygenase 
pathway-derived products (37). 
Leukotriene Release 
Leukotrienes have been detected in a variety of biological 
fluids by employing sensitive assay systems to detect pico- 
gram quantities such as high-performance liquid chroma- 
tography (HPLC), radioimmunoassay and fast-atom 
bombardment mass spectrometry (Table 3). Bronchalveolar 
lavage (BAL) has been used as a tool to obtain fluid in 
pulmonary disease states. Because the ratio of the volume 
of lavage fluid instilled to that recovered is not always 
constant, BAL suffers from the drawback that it is not 
easy to interpret the absolute values given and the results 
are usually expressed in terms of amounts per volume 
recovered. Urine is a more reliable biological fluid and 
amounts of mediator are easily standardized by expressing 
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TABLE 3. Release of leukotrienes into biological fluids 
Disease 
Biological 
fluid Leukotriene release 
Asthma 
Clinical disease 
Symptomatic 
Acute 
Allergen challenge 
Early allergen response 
Aspirin-sensitive 
Exercise-induced 
Cryptogenic-fibrosing alveolitis 
Persistent pulmonary hypertension 
Adult respiratory distress syndrome 
Rheumatoid arthritis 
Gouty arthritis 
Psoriasis 
Inflammatory bowel colitis disease 
Acute myocardial infarction 
Hepatorenal syndrome 
BAL 
BAL 
Urine 
BAL LTC, increases nine-fold 
Urine LTE, increases 24 h after allergen challenge 
Urine LTE, six-fold higher at baseline and increases a further 
BAL 
Urine 
Nasal lavage 
BAL 
BAL 
Pulmonary oedema fluid 
Synovial fluid 
Joint fluid 
Skin chamber fluid 
Intestinal mucosal fluid 
Urine 
Urine 
LTE, detected in mild asthma/severe 
LTB,/LTC, 
LTE, - highest levels in patients responding to &agonist 
treatment 
four-fold after aspirin challenge 
LTB, rises 12-fold and LTC, rises five-fold after 
isocapnic hyperventilation 
LTE, found to increase 1.7-fold in a study of children 
with severe asthma 
LTC, levels increase after lysine-aspirin challenge 
LTB, detected 
LTC, and LTD, detected in newborn infants 
LTD, increased four-fold 
LTB, detected in active disease 
LTB, levels significantly increased 
LTB,, LTC, and LTD, levels detected in increased 
quantities 
LTB, detected in both ulcerative and Crohn’s disease 
LTE, levels raised and return to normal by day 3 
LTE, levels elevated three-fold 
quantities per mg of creatinine which is excreted in rela- 
tively constant fashion throughout a 24-h period (38). 
Maltby et al. found that by infusing three subjects with 
three doses of radiolabelled LTC, it was possible to recover 
a constant 4.1%6.3%, regardless of the amount infused, in 
the form of LTE,, the most stable of the cysteinyl leuko- 
trienes (39). Radiolabelled LTC, instilled into the airways 
of asthmatics, non-asthmatics and asthmatics challenged 
with allergen was found to be excreted in a constant fashion 
in all three groups with LTE, as the major metabolite (40). 
Christie et al. found a significant correlation between the 
dose of inhaled LTC, and the amounts excreted as urinary 
LTE, (41). These studies provide strong evidence for the 
utility of urinary LTE, as a marker of pulmonary cysteinyl 
leukotriene release. 
ALLERGEN-INDUCED ASTHMA 
Leukotriene release has been measured in studies employ- 
ing various bronchial challenge procedures. Wenzel et al. 
reported that, using HPLC, the predominant leukotriene in 
BAL fluid in atopic asthmatic subjects after endobronchial 
bronchial allergen challenge is LTC,, and there was an 
approximate nine-fold rise in levels compared to baseline. 
Measurable levels of LTC, at baseline were found in nine of 
11 atopic asthmatic subjects but in only one of seven atopic 
non-asthmatic subjects and one of six non-atopic subjects. 
There was only a slight rise in BAL LTC, levels after 
allergen in the atopic non-asthmatic group and no change 
in the non-atopic samples (42). In a further study by Wenzel 
et al. the levels of PGD,, TXB,, LTC, and histamine were 
measured in BAL fluid before, and 5 min after, endo- 
bronchial allergen challenge in three groups of atopic 
subjects: seven non-asthmatic; six asthmatic subjects with- 
out a late asthmatic response; and six asthmatic subjects 
with a late asthmatic response. LTC, was detected in 
nine out of the 12 asthmatic subjects but in only one out of 
seven subjects without asthma. Significant increases in all 
mediator levels were observed in both groups with asthma 
post-allergen challenge compared to the non-asthmatic 
group. Interestingly, the asthmatic group without a late 
asthmatic response recorded significantly higher levels of all 
four mediators post-challenge than the groups with a late 
response and the non-asthmatic controls (43). In a study of 
17 allergic asthmatic subjects undergoing allergen provoca- 
tion, there was a fall in FEV, within the first 2 h of between 
25% and 59% and this was accompanied by a rise in urinary 
LTE, levels from 46 ng to 92 ng over a 12 h collection 
period. Methacholine challenge alone, which led to similar 
falls in FEV,, did not significantly change urinary LTE, 
excretion. There was a significant correlation between the 
decrease in FEV, during the early asthmatic response 
(EAR), the excretion of urinary LTE, and the airways 
reactivity. No correlation was found between urinary LTE, 
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excretion and the severity of the late response to allergen 
but there was a significant prolonged elevated urinary 
LTE, excretion in those patients with the most severe 
late asthmatic responses (40). Manning et al. studied 18 
asthmatic subjects who were divided into three groups: 
those with an isolated EAR; those with an isolated late 
asthmatic response (LAR); and a third group with a dual 
asthmatic response (DAR) (44). Urinary LTE, rose signifi- 
cantly from baseline values only in the two groups with an 
EAR, with a rise from 150 to 1816 pg rng- ’ creatinine in 
the group with an isolated EAR and a rise from 66 to 
174pgmgg’ creatinine in the group with an EAR preced- 
ing a LAR. No increase in urinary LTE, was found in the 
group with an isolated LAR. Furthermore, the degree of 
maximum bronchoconstriction during the EAR correlated 
with urinary LTE, release suggesting that the cysteinyl 
leukotrienes are only released during the EAR and that 
they contribute significantly to the bronchoconstriction 
found during this phase of the asthmatic response. Several 
subsequent studies have also documented urinary LTE, 
release 2-4 h following specific bronchial allergen challenge 
(45,46). 
EXERCISE-INDUCED ASTHMA 
Pliss et al. found increases in BAL fluid levels of LTB, from 
10 to 121 pg ml ~ ’ and immunoreactive cysteinyl leuko- 
trienes from 46 to 251 pg ml- i following isocapnic hyper- 
ventilation as a model for exercise-induced asthma (47). 
There were also increases in eosinophil and epithelial cell 
numbers but no changes in prostaglandin or histamine 
levels were detected. Urinary levels of LTE, were not found 
to increase in a study of six asthmatic subjects after 
treadmill leading to a mean 22% fall in FEV, (48). How- 
ever, small increases in urinary LTE, (14.3 before and 
24.3ngmgg’ creatinine after exercise) were found in eight 
out of ten children with severe asthma following exercise 
which produced a 60% fall in FEV,, but no increases in 
urinary LTE, in seven children with moderate asthma who 
experienced only a 24% fall in FEV, (49). Despite the 
conflicting evidence, pharmacological studies have indi- 
cated an important role for cysteinyl leukotrienes in 
exercise-induced bronchospasm. It is likely that our inabil- 
ity to detect these mediators consistently in biological fluids 
may be because whole body cysteinyl leukotriene release 
does not change significantly after exercise which may be 
further modified by changes in bronchial or pulmonary 
blood flow in response to airway cooling and local changes 
in pH and osmolarity. Furthermore, the modest local 
increases in cysteinyl leukotriene release in exercise-induced 
asthma are likely to be difficult to detect with currently 
employed assays. 
ASPIRIN-SENSITIVE ASTHMA 
The cysteinyl leukotrienes have considerable importance in 
the pathogenesis of aspirin-sensitive asthma (ASA). Mean 
resting urinary LTE, levels in aspirin-sensitive asthmatic 
subjects are significantly higher than in normals or non- 
aspirin sensitive asthmatics. Christie and colleagues found 
six-fold higher urinary LTE, levels in aspirin-sensitive 
subjects compared to non-aspirin sensitive asthmatic con- 
trols (50). Furthermore, oral aspirin challenge which led to 
a mean 21% fall in FEV, in six ASA subjects resulted in a 
four-fold increase in urinary LTE, values over baseline 
values. There was no such increase in urinary LTE, levels 
in the control subjects and no fall in FEV, on aspirin 
ingestion. Smith and colleagues reported that baseline 
urinary LTE, levels in ten ASA subjects were 101 pg mg - ’ 
creatinine compared to 43 pg mg - i creatinine in 31 
non-aspirin sensitive asthmatic subjects, and 34 pg mg - i 
creatinine in 17 normals (38). There was substantial overlap 
between the groups and no correlation was found between 
urinary LTE, and histamine PD20 or baseline FEV, and so 
measurement of LTE, in a single sample of urine does not 
predict the degree of resting airflow obstruction or the 
degree of bronchial hyperresponsiveness, or diagnose 
aspirin sensitivity. Recent studies have also confirmed 
increased urinary LTE, levels in ASA subjects following 
iysine-aspirin bronchial challenge (5 1,52). Nasal lavage 
mediator levels have been studied in aspirin-sensitive 
rhinosinusitis. Following lysine-aspirin challenge, increased 
levels of both histamine and LTC, were detected in nasal 
lavage samples in three out of four ASA subjects with 
both naso-ocular symptoms and a bronchospastic reaction. 
No increases in these mediators was found in normals or 
non aspirin-sensitive subjects or aspirin-sensitive subjects 
in whom lysine-aspirin did not provoke naso-ocular 
symptoms (53). 
CHRONIC ASTHMA 
On bronchoalveolar lavage, 15 out of 17 asthmatic sub- 
jects with mild to severe disease were found to have 
detectable LTE, in BAL fluid but there was no corre- 
lation between LTE, levels and pulmonary function. 
None of the group of nine control subjects had detectable 
LTE, (54). In a study by Wardlaw et al., eight sympto- 
matic asthmatic subjects had significantly higher levels of 
BAL LTB, and LTC, than a control group of 14 without 
asthma (55). In a study using urinary LTE, as a marker 
for pulmonary cysteinyl leukotriene release, Smith and 
colleagues found no difference in baseline urinary levels of 
LTE, between 17 normal and 31 asthmatic subjects. In 
addition, there was no correlation between urinary LTE, 
levels as measured in pg mg ~ ’ of creatinine, and baseline 
airways responsiveness to histamine or FEV, as a per cent 
of predicted values (38). Drazen et al. examined 72 sub- 
jects presenting to accident and emergency and classified 
22 patients with a doubling of peak expiratory flow rate 
(PEFR) following nebulized salbutamol as responders, 
and 19 patients with a less than 25% increase in PEFR as 
non-responders (56). Urinary LTE, levels were assayed 
by pre-column extraction, HPLC and radioimmuno- 
assay in these two groups and compared to 13 normal 
controls. Urinary LTE, levels were significantly higher in 
responders compared to non-responders or normal sub- 
jects. The authors concluded that the highest levels 
of LTE, found in those with acute reversible airflow 
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obstruction was consistent with a bronchospastic role for 
cysteinyl leukotrienes in spontaneous acute asthma. 
RHINOSINUSITIS 
Evidence for the role of LTs in the pathogenesis of rhino- 
sinusitis comes from studies of the nasal lavage fluid 
obtained during the early- and late-phase reactions after 
nasal allergen challenge; in spontaneous rhinitis during 
seasonal allergen exposure; after topical leukotriene 
challenge; and from clinical studies demonstrating the 
clinical efficacy of leukotriene antagonists (57). Although 
the majority of the signs and symptoms of allergic rhino- 
sinusitis are believed to be mediated by histamine (and 
effectively relieved by antihistamines), nasal allergen 
challenge results in increased cysteinyl LTs in nasal lavage 
fluid, and in tear fluid during both early- and late-phase 
inflammation and during natural exposure. Various studies 
have demonstrated a dose- and time-dependent release of 
predominantly LTC, into the nasal lavage fluid, which 
peaks at 10 min after nasal challenge with allergen but not 
with methacholine (5859). Levels of LTC, are also elevated 
during the late-phase response although the absolute quan- 
tity is much lower. In addition, if patients with ragweed 
sensitive allergic rhinosinusitis are challenged with specific 
allergen there is an early inflammatory cellular infiltrate 
associated with LTC, generation in the nasal lavage fluid 
(60,61). Moreover, increased levels of LTC, have been 
found to peak at weeks 3 and 10 during natural grass pollen 
and ragweed exposure during the hay-fever season (62,63). 
Furthermore, increased levels of eosinophils LTC, and 
LTD, have been found in increased amounts in the nasal 
lavage fluid from patients with chronic perennial rhino- 
sinusitis (64). Allergic rhinosinusitis is characterized by 
epithelial infiltration of activated mast cells, basophils and 
eosinophils and a submucosal infiltration of eosinophils 
and activated Th,-type CD4+ve T lymphocytes (65-67). 
Mast cells and eosinophils are abundant cellular sources of 
the increased levels of LTC,, as described above. Bisgaard 
et al. demonstrated that nasal challenge with LTD, 
increased nasal blood flow and resistance but did not 
increase nasal secretions or induce itching and sneezing 
(68). Okuda et al. found similar results and showed that the 
duration of the LTD,-induced increase in nasal resistance 
exceeded that of histamine and was similar to that observed 
after allergen challenge (69). In addition, LTD, was found 
to be 5000 times more potent than histamine on a weight 
basis. Thus, LTs would appear to be responsible predomi- 
nantly for the vascular congestion and nasal blockage 
associated with rhinitis. 
Anti-leukotriene Therapy 
LT action may be pharmacologically modulated by 
antagonism at the receptor site or by biosynthesis 
inhibition. LTB, receptor antagonists have not yet been 
evaluated in humans, but LTD, receptor antagonists have 
been developed for use in human trials. Inhibition of 5-LO 
biosynthesis is effected either by direct interference with its 
enzymatic properties, or by secondary inhibition of its 
interaction with FLAP. A large number of clinical trials 
have been completed with these agents, establishing their 
efficacy in the treatment of spontaneous or induced asthma. 
All drugs have been shown to provide a superior effect, 
when compared to placebo, in the treatment of patients 
with mild-to-moderate asthma. For example, in trials of 
4-6 weeks duration, individuals with moderate asthma 
(average FEV, values of about 65% of predicted) treated 
only with P-agonists were randomized in a double-blind 
fashion to either active agent or placebo. Patients receiving 
either zileuton, zafirlukast, or montelukast had a lo-15% 
improvement in FEV,; this benefit was statistically signifi- 
cant when compared to the placebo group. Active therapy 
was also associated with both a significant decrease in the 
need for rescue P-agonist therapy and improved asthma 
symptoms, especially at night (70,71). These results are 
similar in magnitude to those achieved with inhaled steroids 
given at recommended doses. 
LEUKOTRIENE RECEPTOR ANTAGONISTS 
The first antagonist to be evaluated was the hydroxy- 
acetophenone FPL 55712 which had demonstrated selective 
activity as an inhibitor of SRS-A even before the chemical 
structure of SRS-A was elucidated (72). However, it proved 
disappointing in clinical trials of asthma because of low 
potency, a short half-life and bioavailability only by in- 
halation (73). Other first generation LTD, antagonists to be 
evaluated in humans include L-648,051, L-649,923, 
LY-171,883, LY-170,680, and SK&F 104,353 (74-78). 
These compounds were of modest potency with a rightward 
shift in the LTD, dose-response curve of three- to ten-fold 
with poor to moderate clinical efficacy in early trials. 
More recently, highly selective, second-generation LTD, 
antagonists have been developed with up to loo-fold 
greater potency than FPL 55712. The most potent of these 
compounds include: zafirlukast (Accolate@, ICI 204,219) 
with potency up to lOOO-fold greater than FPL 55712 in 
inhibiting contraction of guinea-pig tracheal and parenchy- 
ma1 strips (79); ON0 1078 (Pranlukast) which causes a 
loo-fold rightward shift of the LTD, dose-response curve; 
MK-571, a member of a family of quinolone-derived LTD, 
antagonists that show a 44- to 84-fold rightward shift in the 
LTD, dose-response curve in asthmatic subjects (80). In 
addition, MK-0476 (montelukast) has recently been shown 
to be a highly potent and long-lasting antagonist of LTD,- 
induced bronchoconstriction in patients with asthma (8 1). 
Allergen-induced asthma 
In early studies, LY-171,883, which has a similar structure 
to FPL 55712 and L-649,923, showed a slight reduction of 
the EAR, but had no effect on baseline lung function or the 
LAR (82,83). In a study of ten asthmatics, a single oral dose 
of 40 mg zafirlukast, a highly selective and potent LTD, 
antagonist, attenuated the EAR by 80% and the LAR by 
50%, and reduced the allergen-induced rise in non-specific 
BHR at 6 h post-challenge (84). An inhaled formulation of 
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zafirlukast was less effective but still significantly inhibited 
the EAR but not the LAR (85). A further study using a 
single inhaled dose of 40 mg zafirlukast displaced the 
allergen dose-response curve to inhaled cat-allergen 
ten-fold compared with placebo; the same inhaled formu- 
lation was shown to shorten the recovery time of the EAR 
from 60 to 40 min (8687). In a study of asthmatic subjects, 
the quinolone derivative MK 571 substantially inhibited the 
EAR by 88% and the LAR by 63% (88). 
Aspirin-sensitive asthma 
Current evidence suggests that aspirin-sensitive asthma is 
the most leukotriene dependent model presently available 
for the evaluation of anti-leukotriene therapy in asthma. 
The weak LTD, antagonist SK&F 104,353, administered 
by the inhaled route, demonstrated inhibition of the bron- 
choconstrictor response to ingested aspirin by a mean of 
47% in five out of six subjects (89). In a study of eight 
subjects with ASA, MK-0679 improved baseline pulmonary 
function and significantly attenuated the airways obstruc- 
tion produced by inhaled lysine-aspirin with a median 
4.4-fold rightward shift in the dose-response curve (90). 
Exercise challenge and isocapnic hyperventilation 
Provided respiratory heat exchange is matched in a time- 
dependent manner, the degree of bronchospasm achieved 
by exercise can be mimicked by controlled isocapnic hyper- 
ventilation. Exercise and isocapnic hyperventilation are 
considered to stimulate similar if not identical pathological 
effector mechanisms for the initiation of bronchoconstric- 
tion. In a study of 20 asthmatic subjects treated for 2 weeks 
with LY-171,883, the geometric mean respiratory heat loss 
required to reduce FEV, was increased by 20%, and there 
was also a marginal reduction of bronchoconstriction 
induced by isocapnic hyperventilation of cold air. In this 
study the most reactive subjects showed greatest protection 
(91). 
Inhaled SK&F 104,353, a weak LTD, antagonist, 
reduced the exercise-induced bronchoconstrictor response 
from 29% to 20% with similar efficacy to disodium cromo- 
glycate (92). During a treadmill exercise challenge involving 
eight asthmatic subjects breathing cold dry air, a 20 mg oral 
dose of zafirlukast reduced the fall in FEV, from 36% to 
21.6% (86). 
In a study of nine subjects undergoing exercise challenge, 
inhaled zafirlukast reduced the exercise-induced fall in 
FEV, (93). MK-571 produced similar results with a 70% 
attenuation of the exercise-induced decrease in FEV, in 12 
asthmatic subjects, and a marked reduction in recovery 
time from 33 to 8 min (94). Pre-dosing with a once daily 
dose of montelukast was able to attenuate exercise-induced 
bronchoconstriction in a dose-related fashion in adults as 
well as in 6- to 14-year-old children (95,96). In addition, it 
attenuated the exercise-induced increase in urinary LTD, 
(97). Despite their potency, these LTD, antagonists were 
unable to completely inhibit the bronchoconstrictor 
response to exercise. This suggests that other mediators 
such as mast cell derived histamine or prostaglandins are 
involved in the pathogenesis of exercise-induced asthma. 
Strek has recently reported that pranlukast can significantly 
inhibit cold air-induced bronchoconstriction in patients 
with asthma (98). 
Bronchodilation 
Ellis and Undem found that isolated human bronchi of 
3-12 mm in diameter had a high degree of intrinsic bron- 
chomotor tone which was on average more than 50% of the 
available maximal constrictor response to 30 mm 1 - ’ 
BaCI,. In the presence of the LTD, agonists zafirlukast or 
SKF 104,353, there was relaxation of the bronchi; this effect 
was additive with a histamine H, antagonist leading to the 
conclusion that intrinsic bronchomotor tone is caused by 
the continual production of cysteinyl leukotrienes and 
histamine (99). 
Further clinical studies have now been carried out to 
support a role for cysteinyl leukotrienes in the maintenance 
of intrinsic bronchial muscle tone. An intravenous infusion 
of the LTD, antagonist MK-0679 in nine asthmatic 
patients with baseline FEV, ranging from 40% to 80% of 
predicted values, produced an increase in FEV, of 15.8% 
and 7.8% with 500 mg and 125 mg, respectively, and a fall 
of 2.6% 15 min after placebo infusion (100). 
In a separate study, an oral dose of 40 mg zafirlukast 
produced a significant resting increase in FEV, compared 
with placebo, and the effect persisted after inhalation 
salbutamol (101). In a study of 12 male asthmatic patients, 
there was further confirmation of the additive effect of 
inhaled /&-agonist administration. The maximum broncho- 
dilation achieved from the start of a 6 h intravenous 
infusion of MK-571 was 22% compared with 1.3% after 
placebo. Administration of salbutamol 5-6 h from the start 
of the infusion produced additional bronchodilatation. The 
overall degree of bronchodilatation correlated inversely 
with baseline FEV,, suggesting a major contribution from 
cysteinyl leukotrienes in resting airway tone (102). A study 
with aspirin sensitive asthmatics examined the magnitude of 
cysteinyl leukotriene effect on intrinsic airway tone using a 
single dose of 825 mg MK-0679 in eight subjects. A mean 
peak increase in FEV, of 18% was observed with a range of 
5-34% and correlated strongly with the severity of asthma 
(103). A recent study by Reiss et al. has demonstrated that 
montelukast at 100 mg or 250 mg orally induces a signifi- 
cant increase in FEV, in patients with mild to moderate 
asthma, irrespective of whether the patient is taking con- 
comitant inhaled GCS (11). In addition, a recent report by 
Smith et al. has demonstrated that pranlukast can inhibit 
LTD,-induced bronchoconstriction in patients with asthma 
(104). 
Chronic asthma 
The leukotriene receptor antagonists have shown consider- 
able efficacy in models of experimental asthma and there 
are now many studies demonstrating efficacy in clinical 
asthma. In a multicentre, placebo-controlled study, 138 
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patients with asthma received LY-171,883 1200 mg day-’ 
for 6 weeks (105). In the treatment group, mean FEV, rose 
significantly from 73.8% to 83.3% of predicted values, 
compared with placebo. There were also significant 
improvements in the severity of day-time and nocturnal 
wheeze and breathlessness, with a significant reduction in 
P,-agonist use, although there was no change in symptoms 
of cough or chest tightness. In a separate study, treatment 
with 225 mg t.d.s. MK-571 for 2 weeks followed by 4 weeks 
of treatment with 150 mg t.i.d. produced a mean S-14% 
improvement in FEV, and a 30% reduction in morning and 
evening symptom scores, accompanied by a 30% reduction 
in salbutamol usage (102). A recent study of montelukast 
has shown similar efficacy irrespective of the presence of 
inhaled GCS (106). One week’s treatment with ONO-1078 
in a crossover study of 11 asthmatic subjects produced a 
significant decrease in methacholine bronchial responsive- 
ness as compared with placebo; there was no change in 
either resting FEV, or forced vital capacity (FVC) during 
that period (107). 
In a placebo-controlled, dose-ranging study of 266 sub- 
jects with moderate asthma, treatment with 40 mg b.d. 
zafirlukast over 6 weeks was more effective than 20 mg b.d. 
or 10 mg b.d. without any increase in adverse effects. 
Compared with placebo there was a significant reduction in 
nocturnal awakenings (by 46%), first morning asthma 
symptoms, day-time asthma scores (by 26X), salbutamol 
use (by 30%) and an increase in FEV, (11%) and evening 
peak expiratory flow rates (71). The largest study reported 
to date is that of Fish and colleagues who demonstrated 
that zafirlukast 20 mg b.d. was more effective than inhaled 
&agonists alone in 762 patients with moderate asthma 
over a 13-week study period (108). This effect was also seen 
by Suissa in a smaller study (109). These studies highlight 
the need for a direct comparison of zafirlukast with inhaled 
glucocorticoids in these patients. Although the toxicity 
profile of this drug is excellent, a recent report has linked its 
usage to the development of a rare Churg-Strauss-type 
syndrome in eight patients (seven women, one man) using 
this drug (110). The clinical syndrome developed in gluco- 
corticoid dependent patients when receiving zafirlukast 
from 3 days to 4 months following attempted glucocorti- 
coid withdrawal. It is unclear whether these patients had a 
primary steroid dependent pulmonary infiltrative disorder 
that had been clinically recognized as asthma which was 
eventually unmasked by steroid withdrawal or whether this 
effect is a rare side-effect of this drug. 
One study has reported that adding an LTD, receptor 
antagonist (10 days treatment with RG 12 525) to existing 
therapy with inhaled steroids significantly improved FEV, 
in stable asthmatic subjects (111). A recent study by 
Tamaoki et al. has shown that pranlukast can allow 
halving of high dose inhaled steroids over a 6-week period 
without a deterioration in asthma control (112). This 
effect was not seen in patients who required oral pred- 
nisolone (113). In addition, Barnes et al. has recently 
demonstrated that pranlukast improved symptom scores 
and rescue bronchodilator use in a 4 week study (114). 
The drug was well tolerated, improved FEV, within 1 h of 
oral dosing which was maintained for 8 h (115). Further 
and larger scale studies are required to predict accurately 
the future role of leukotriene antagonists in asthma 
therapy, and determine whether their major role is as 
bronchodilators, anti-inflammatory agents, or whether 
they can replace existing treatments such as inhaled corti- 
costeroids or theophyllines. These smaller studies of rela- 
tively short duration would suggest that these drugs can 
bronchodilate, are as effective as theophylline and can act 
as steroid sparing agents. 
Rhinitis 
In contrast to asthma there are relatively few trials available 
on the effectiveness of LT receptor antagonists in rhinitis. 
Flowers found that L-649,923 was ineffective at blocking 
the early response to nasal challenge in 12 patients with 
grass pollen-sensitive rhinitis in a cross-over study (116). 
Donnelly et al. has tested the efficacy and safety of single 
oral doses of zafirlukast in 162 subjects with acute seasonal 
allergic rhinitis and found that 20 mg and 40 mg effectively 
attenuated the rhinitic symptoms after 2 h post-dose with 
no serious adverse events reported (117). Zafirlukast was 
able to reduce both sneezing and rhinorrhoea in this study 
and is contrary to the results obtained with intranasal 
LTD, provocation (68). This discrepancy may be due to the 
release of LTD, in conjunction with other mediators of 
inflammation in the clinical setting. Grossman et al. have 
recently reported that pranlukast (Ultair@‘) significantly 
relieves symptoms in patients with seasonal allergic rhinitis 
(118). 
LEUKOTRIENE BIOSYNTHESIS INHIBITORS 
Inhibitors of leukotriene biosynthesis were thought to be 
more effective than LTD, receptor antagonists in prevent- 
ing the pathophysiological consequences of leukotriene 
release within the airways because of the dual inhibition of 
both LTD, and cysteinyl leukotriene generation. Current 
evidence suggests that 5-LO contains a non-haem iron that 
is normally in the dormant ferrous state (Fe”) and, upon 
activation by hydroperoxides, adenosine triphosphate 
(ATP) and calcium, is converted to the active ferric form 
(Fe3+). Some 5-LO inhibitors have more than one mode of 
action. At low concentrations of racaemic WY-50,295, 
inhibition of 5-LO binding to FLAP predominates but at 
higher concentrations its activity as an arachidonic acid 
analogue becomes more significant (119). Hydroxamic 
acides and hydroxyureas act primarily by chelating the 
essential iron at the active site of the enzyme but are also 
likely to have additional antioxidant activity (120). Clinical 
trials involving 5-LO inhibitors have followed the pattern 
set by the cysteinyl leukotriene receptor antagonists with 
earlier studies using compounds, such as piriprost, with 
weak inhibitory activity, which demonstrated little clinical 
use. 
Allergen-induced asthma 
In a single-dose, placebo-controlled crossover study, nine 
asthmatic subjects received the iron chelator zileuton 
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(A64077). Despite almost complete inhibition of ex viva 
whole blood LTB, generation and 50% reduction of the rise 
of urinary LTE,, there was no significant attenuation of the 
early or late asthmatic response, and no decrease of the 
airway responsiveness to methacholine (121). The potent 
and selective non-redox 5-LO inhibitor ZD2138 was evalu- 
ated in a study of eight asthmatic subjects and although 
there was an 82% reduction of ex viva LTB, generation in 
whole blood and an overall 72% inhibition of the rise in 
urinary LTE, excretion, again there was no inhibition of 
the allergen-induced early or late asthmatic response (46). 
In a separate placebo-controlled study of eight atopic 
men, the FLAP inhibitor MK-886 was given 1 h before 
(500 mg) and 2 h after (250 mg) allergen inhalation. 
MK-886 inhibited the early asthmatic response by 58% and 
the late asthmatic response by 44%. This was accompanied 
by a 54.2% inhibition of A23187 stimulated whole blood 
LTB, generation and a 51.5% inhibition of the rise in 
urinary LTE, during the early, and 80% during the late, 
asthmatic response. However, compared with placebo, no 
significant change in airways responsiveness to histamine 
was observed at 30 h after allergen challenge (122). In 
another study, the FLAP inhibitor MK-0591 (250 mg) was 
administered at 24, 12, and 1.5 h before allergen inhalation. 
Over the 24 h period following allergen inhalation, LTB, 
generation was inhibited by 96% and urinary LTE, excre- 
tion by 84%. The early asthmatic response to allergen was 
inhibited by 79% and the late asthmatic response delayed 
by 3 h. No effect was observed on airway responsiveness to 
histamine 24 h post-allergen challenge (123). 
Aspirin-induced asthma 
The effect of aspirin ingestion was examined in eight 
subjects with ASA and hyperexcretion of urinary LTE, 
who were premeditated with zileuton or placebo. Zileuton 
reduced baseline urinary LTE, excretion by 70% and 
prevented the fall in FEV, in response to aspirin challenge. 
In addition, there was protection against the development 
of nasal, gastrointestinal, and dermal symptoms in response 
to aspirin ingestion (124). 
In a separate study, seven subjects with aspirin-induced 
asthma and hyperexcretion of urinary LTE, were premedi- 
cated with a single dose of 350 mg ZD2138 which provided 
substantial inhibition of both LTB, generation and urinary 
LTE, excretion. In response to oral aspirin challenge, the 
mean maximum fall in FEV, was 20.3% after placebo and 
4.9% following ZD2138 premeditation associated with a 
reduction in systemic symptoms (125). 
Exercise-induced asthma 
A single 800 mg dose of zileuton administered to 13 
asthmatic subjects inhibited ex vivo whole blood LTB, 
generation by 74% without affecting TXB, levels. This 
produced a 47% increase in the amount of cold dry air 
required to reduce FEV, by 10% with an increase in minute 
ventilation from 27.5 1 min- ’ to 39.8 1 min- ’ (126). A 
further study of 24 subjects with mild asthma, premeditated 
for 2 days with zileuton 2.4 g day- ’ showed a 40% inhibi- 
tion of exercise-induced bronchospasm. The study also 
showed a significant protection against the fall in FVC 
compared with placebo (70,127). 
Chronic asthma 
As part of a multicentre study, 139 asthmatic patients, not 
taking oral or inhaled corticosteroids and with baseline 
FEV, values of 40-75%, were placed on placebo or zileuton 
2.4 g or 1.6 g day - ’ for 4 weeks (70). Patients treated with 
zileuton had a statistically significant 13.6% improvement 
in FEV, after 4 weeks therapy. There was also a significant 
improvement in asthmatic symptom scores and a reduction 
in &agonist use in subjects on the higher dose of zileuton. 
In an extension of this study, 398 asthmatic patients with 
moderately severe asthma (baseline FEV, 61%) and who 
had been previously stabilized on salbutamol were treated 
for 13 weeks with either 2.4 g or 1.6 g day- r zileuton or 
placebo. In the subjects taking 2.4 g day- ’ zileuton there 
was a sustained increase in FEV, of 0.25 1 compared with a 
0.08 1 increase in the patients receiving placebo. 
In a separate study, 109 asthmatic subjects taking 
400-1600 mg of either beclomethasone or budesonide with 
baseline FEV, 50-75% were placed on placebo or 125 mg 
MK-0591 twice daily (128). After 4 weeks’ treatment, FEV, 
increased by 6.8% in the MK-0591-treated group compared 
with an increase of 0.6% in the placebo-treated group. In 
addition, there was an increase in morning and evening 
PEFR of 19% and 13%, respectively, in the MK-0591 
treated group, compared with a fall in morning and evening 
PEFR of 5% and 6%, respectively, in the placebo group. 
Furthermore, subjects on active treatment reported a 
reduction in &agonist use. A recent study by Liu 
et al. assessed the effects of two doses of Zileuton in 122 
patients with mild to moderate asthma (129). Zileuton 
produced an acute bronchodilatory response, 2-5 hours 
after initial dosing. In addition, zileuton improved FEV, 
morning peak flows and reduced f12 agonist use and eosino- 
phi1 count. In a recently published, longer-term trial of 
zileuton, 401 patients were randomized in a double-blind 
fashion to 3 months of therapy with placebo or with one of 
two doses of zileuton, 400 mg or 600 mg four times a day 
(131). There was a significant increase in FEV, with zileu- 
ton compared with placebo (16% in the 600 mg group vs 8% 
in the placebo group) and a significantly lower percentage 
of patients who required treatment with corticosteroids (6 
vs 16%). The main adverse effect was an approximately 2% 
incidence of elevated plasma transaminase levels, which 
reversed with drug withdrawal. In long-term safety studies, 
approximately 5% of patients treated with zileuton had 
clinically significant increases in transaminases, while the 
usual care group had an increase in 2% of patients. Patients 
treated with zileuton will require monitoring of liver func- 
tion tests at the onset of treatment and periodically there- 
after. This complication, occurring within the first months 
of therapy, has not been observed with zafirlukast; public 
data have not been made available for pranlukast or 
montelukast. A recent study has suggested that patients 
who demonstrate improved asthma control on zileuton 
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600 mg q.d.s. may be able to reduce their daily dose and/or 
frequency of administration while still maintaining the 
same level of symptom control, which has obvious implica- 
tions for toxicity (132). In addition, a recent study by 
Schwartz has shown that zileuton appears to be as effective 
and as safe as theophylline in patients with chronic asthma 
over the 14-week study period (133). 
In clinical studies, leukotriene receptor antagonists have 
proven as effective as biosynthesis inhibitors in suppressing 
cysteinyl leukotriene mediated disease processes. Specula- 
tion suggests that the ideal compound to modulate the 
effects of leukotrienes in asthma would possess both leuko- 
triene receptor antagonism and 5-LO synthesis inhibitory 
activity because these activities may be functionally addi- 
tive. Over the next few years, the place of anti-leukotriene 
therapy in the treatment of asthma is likely to be estab- 
lished; first, however, more clinical studies are required to 
define whether they possess glucocorticoid-sparing activity, 
lead to long-term symptomatic improvement, or affect the 
underlying disease processes. 
Rhinitis 
During the immediate response to nasal allergen in patients 
with allergic rhinosinusitis, the 5-LO inhibitor zileuton 
reduced nasal congestion but did not alter histamine secre- 
tion or sneezing (134). The 5-LO inhibitor, A78773, signifi- 
cantly inhibited the increase in nasal lavage fluid protein 
and histamine levels following allergen challenge in patients 
with allergic rhinosinusitis (135). Knapp examined the effect 
of a single dose of zileuton on symptoms and mediator 
release into the nasal lavage fluid after nasal allergen 
challenge in eight allergic subjects in a double-blind ran- 
domized trial. Zileuton significantly reduced nasal conges- 
tion and the release of LTB, and 5-HETE into the nasal 
fluid (130). There was no effect on sneezing or on histamine 
release. Spaeth et al. has demonstrated that azelastine 
(Astelin) nasal spray was superior to place0 in attenuating 
nasal obstruction after provocation with both histamine 
and allergen (136). Fischer et al. investigated the effects of 
zileuton on the nasal response in patients with confirmed 
aspirin sensitivity (137). One week of zileuton 600 mg q.i.d. 
followed by aspirin challenge greatly reduced the aspirin- 
induced increase in nasal symptoms and the level of 
leukotrienes found in nasal lavage fluids when compared to 
an aspirin challenge prior to taking zileuton. 
Future role of LT antagonists in the treatment of asthma 
and rhinitis 
Agents active on the 5-LO pathway such as zileuton, 
zafirlukast, montelukast and pranlukast are likely to be an 
alternative to inhaled steroids for patients who are using 
P-agonists as their primary asthma treatment, as the efficacy 
of these drugs is clearly established in this setting (138-142). 
It also seems likely that they will be effective adjunctive 
therapy in patients whose asthma is poorly controlled 
despite use of inhaled steroids at a low dose or at a high 
dose, in order to prevent long-term oral steroid exposure 
(143). In the U.K. this would entail introducing montelu- 
kast as add-on therapy at step 3 of the British Thoracic 
Society asthma guidelines. There is reason to believe that 
these drugs will be partially effective preventative therapy 
for patients with exercise-induced asthma. They will play an 
important role as single therapy in patients with co-existing 
asthma and rhinitis and are likely to have a unique place in 
the management of the aspirin-sensitive syndrome. The 
leukotriene inhibitors will not supplant B-agonists since 
their acute bronchodilator effects are not as marked as 
those of b-agonists. Their use in more severe asthma is 
currently under study. 
Conclusion 
LTs have been shown to be central to the pathogenesis of 
bronchial asthma and to contribute to the inflammation of 
allergic rhinitis. Inhibition of their activity has been shown 
to be associated with an improvement of control in these 
disease states. However, their exact role in the management 
of these diseases remains to be established and, in particu- 
lar, comparative studies with topical glucocorticoids are 
eagerly awaited. 
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